Protein tyrosine kinases belonging to the src family

Monocular and Binocular Temporal Visual Perception of Infantile Nystagmus

Contrast sensitivity is mostly used as a tool for testing aspects of visual functions. Infantile nystagmus is a pathological phenomenon that affects the spatial-temporal visual functions due to spontaneous oscillating movements of the eyes. We examined the spatial-temporal aspects of nystagmus perception, aiming to investigate the mechanisms underlying the deterioration of their visual performance. We tested the monocular and binocular contrast sensitivity of nystagmus and normally sighted subjects by measuring contrast detection of a Gabor target with spatial frequencies slightly above the cutoff threshold of each subject (nystagmus ~3; controls = 9cpd; presentation times 60–480 ms). The dominant eye of nystagmus revealed large differences over the non-dominant eye, highlighting the superiority of the dominant over the non-dominant eye in nystagmus. In addition, binocular summation mechanism was impaired in majority of the nystagmus subjects. Furthermore, these differences are not attributed to differences in visual acuity. Moreover, the visual performance in nystagmus continue to improve for longer presentation time compared with controls and was longer in the poor eye. Since the results are not due to differences in eye movements and strabismus, we suggest that the differences are due to developmental impairment in the visual system during the critical period.

A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer

Molecular targeted therapies have been the focus of recent clinical trials for the treatment of patients with recurrent epithelial ovarian cancer (EOC). The majority have not fared well as monotherapies for improving survival of these patients. Poor bioavailability, lack of predictive biomarkers, and the presence of multiple survival pathways can all diminish the success of a targeted agent. Dasatinib is a tyrosine kinase inhibitor of the Src-family kinases (SFK) and in preclinical studies shown to have substantial activity in EOC. However, when evaluated in a phase 2 clinical trial for patients with recurrent or persistent EOC, it was found to have minimal activity. We hypothesized that synthetic lethality screens performed using a cogently designed siRNA library would identify second-site molecular targets that could synergize with SFK inhibition and improve dasatinib efficacy. Using a systematic approach, we performed primary siRNA screening using a library focused on 638 genes corresponding to a network centered on EGFR, HER2, and the SFK-scaffolding proteins BCAR1, NEDD9, and EFS to screen EOC cells in combination with dasatinib. We followed up with validation studies including deconvolution screening, quantitative PCR to confirm effective gene silencing, correlation of gene expression with dasatinib sensitivity, and assessment of the clinical relevance of hits using TCGA ovarian cancer data. A refined list of five candidates (CSNK2A1, DAG1, GRB2, PRKCE, and VAV1) was identified as showing the greatest potential for improving sensitivity to dasatinib in EOC. Of these, CSNK2A1, which codes for the catalytic alpha subunit of protein kinase CK2, was selected for additional evaluation. Synergistic activity of the clinically relevant inhibitor of CK2, CX-4945, with dasatinib in reducing cell proliferation and increasing apoptosis was observed across multiple EOC cell lines. This overall approach to improving drug efficacy can be applied to other targeted agents that have similarly shown poor clinical activity.